We’re LIIRA CARE
Redefining respiratory self-care
Redefining respiratory self-care
LIITA Care is a innovative consumer health company dedicated to the discovery and development of novel therapies that improve the lives of consumers suffering from respiratory diseases
Our mission is to become a global provider of the future go-to solution for respiratory self-care. We do this by transforming the cough and cold category with our portfolio of clinically documented over-the-counter treatments
Our patented technology deploys NaCl microparticles in a new and consumer-friendly treatment form proven to be clinically beneficial in diseases that affect more than 80% of the world's population
Our Product Pipeline
Diversified and innovative pipeline including late-stage assets open the opportunity for position as global go-to brand for NaCl particle inhalation
Latest News
Catch up on the latest news & updates here
05 September 2022 • Press Release
LIITA Research to be Presented at the ERS Congress 2022
We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
02 September 2022 • Media Update
LIITA Research to be Presented at ERS Congress 2022
We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
Come join us Monday the 5th of September at 12.45 pm (Room 8L).
2022 • News Article
Stay tuned for more news
TBA
Board of Directors
Board member
Henrik Kjær Hansen
Novo Holdings
Board member
Jakob Ottesen Thiesson
Boston Consulting Group
Board member
Søren Dannelund Reipurth
Lundgrens
Board member
Bjørn Bruun
Investor
Management
CEO & Founder
Martin Ohrt
LIITA Care
CFO
Søren Kjær Henningsen
LIITA Care
Latest News
Catch up on the latest news & updates here
Latest News
Catch up on the latest news & updates here
What We Do
Creating respiratory self-care solutions
We are focused on creating a respiratory self-care portfolio, based on our proprietary inhalation technology for civilian and defence markets.
Products
-
Dry/Wet Salt
-
Nasal/Oral
Indications
-
Antiviral
-
Anti-inflammatory
-
Pediatric
Dual-Use Platform
Introducing a transformative treatment form the worlds most prevalent disease in a 41bn€ market.
Civic
Providing a versatile and safe treatment and protection against future pandemics.
Crisis
Relief
Defence
Enhance military readiness by reducing downtime and misuse of antibiotics.